How to Lose Weight After Taking Cymbalta. Cymbalta is commonly prescribed for the treatment of depression, fibromyalgia and anxiety disorder. One of the side effects of taking Cymbalta can be loss of appetite or weight loss, according to Cymbalta. After you stop taking Cymbalta, you may experience changes in your weight once you regain your appetite. Anyone on Cymbalta and loosing weight on it? Add as Friend Message. The side effects of Cymbalta are nausea,vomiting,diahorrea, and weight loss. An improved appetite associated with improved mood may result in increased weight after taking an antidepressant, notes Mayo. Clinic. com. Adopt healthy eating habits and engage in regular exercise to keep extra pounds at bay and lose additional weight after taking Cymbalta. Manage the calories you eat. Avoid overeating by recording your meals using an online food journal like LIVESTRONG's My. Plate. Watch your calorie intake for a week to see your average. Lose about 1 lb. Eat lean proteins like skinless poultry, beef, fish, eggs, soybeans and other legumes to help build muscle and increase metabolism. Consume complex carbohydrates like whole grains, vegetables and fruits that digest slowly and help you feel fuller while eating less.
Keep healthy snacks handy so they are easily accessible. Fill your kitchen with fresh fruits, vegetables and nuts so you have healthier options when you get the urge to snack. Eat clean and avoid processed foods. Stay away from pre- seasoned, packaged, and high sodium canned goods that encourage weight gain, notes BBC News. Stick to whole foods in their natural form. Exercise regularly. Perform strength training at least three days per week to build muscle which helps you burn more calories per day. Include compound exercises like lunges, squats and push- ups that work multiple muscle groups to burn more calories in less time, notes Bodybuilding. Engage in cardiovascular activity three to five days per week to burn stored body fat. Take a group fitness class, walk on the treadmill, jog outside or bike. Change up your cardio choices often to keep your body constantly responding. Consumer ratings reports for CYMBALTA. Includes patient rankings on scale of 1-5, comments, side effects, dosage, sex, age, time taken.Side Effects, Interactions, Warning, Dosage & Uses. WARNINGSIncluded as part of the . Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest. There has been a long- standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short- term placebo- controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 1. MDD) and other psychiatric disorders. Short- term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 2. Weight gain is a less common side effect of taking Cymbalta. In studies conducted on Cymbalta, weight gain was reported by about. The pooled analyses of placebo- controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 2. The pooled analyses of placebo- controlled trials in adults with MDD or other psychiatric disorders included a total of 2. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug- placebo difference in the number of cases of suicidality per 1. Table 1. Table 1. Age Range. Drug- Placebo Difference in Number of Cases of Suicidality per 1. Patients Treated. Increases Compared to Placebo< 1. Decreases Compared to Placebo. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer- term use, i. However, there is substantial evidence from placebo- controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that discontinuation can be associated with certain symptoms . Such monitoring should include daily observation by families and caregivers. Prescriptions for CYMBALTA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. Screening Patients For Bipolar Disorder. A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to. It should be noted that CYMBALTA is not approved for use in treating bipolar depression. Hepatotoxicity. There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA. These cases have presented as hepatitis with abdominal pain, hepatomegaly, and elevation of transaminase levels to more than twenty times the upper limit of normal with or without jaundice, reflecting a mixed or hepatocellular pattern of liver injury. CYMBALTA should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Cases of cholestatic jaundice with minimal elevation of transaminase levels have also been reported. Other postmarketing reports indicate that elevated transaminases, bilirubin, and alkaline phosphatase have occurred in patients with chronic liver disease or cirrhosis. CYMBALTA increased the risk of elevation of serum transaminase levels in development program clinical trials. Liver transaminase elevations resulted in the discontinuation of 0. CYMBALTA- treated patients. In most patients, the median time to detection of the transaminase elevation was about two months. In adult placebo- controlled trials in any indication, for patients with normal and abnormal baseline ALT values, elevation of ALT > 3 times the upper limit of normal occurred in 1. CYMBALTA- treated patients compared to 0. In adult placebo- controlled studies using a fixed dose design, there was evidence of a dose response relationship for ALT and AST elevation of > 3 times the upper limit of normal and > 5 times the upper limit of normal, respectively. Because it is possible that CYMBALTA and alcohol may interact to cause liver injury or that CYMBALTA may aggravate pre- existing liver disease, CYMBALTA should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. Orthostatic Hypotension, Falls And Syncope. Orthostatic hypotension, falls and syncope have been reported with therapeutic doses of CYMBALTA. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during CYMBALTA treatment, particularly after dose increases. The risk of falling appears to be related to the degree of orthostatic decrease in blood pressure as well as other factors that may increase the underlying risk of falls. In an analysis of patients from all placebo- controlled trials, patients treated with CYMBALTA reported a higher rate of falls compared to patients treated with placebo. Risk appears to be related to the presence of orthostatic decrease in blood pressure. The risk of blood pressure decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1. A2 inhibitors . Consideration should be given to dose reduction or discontinuation of CYMBALTA in patients who experience symptomatic orthostatic hypotension, falls and/or syncope during CYMBALTA therapy. Risk of falling also appeared to be proportional to a patient’s underlying risk for falls and appeared to increase steadily with age. As elderly patients tend to have a higher underlying risk for falls due to a higher prevalence of risk factors such as use of multiple medications, medical comorbidities and gait disturbances, the impact of increasing age by itself is unclear. Falls with serious consequences including bone fractures and hospitalizations have been reported . John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Serotonin syndrome symptoms may include mental status changes (e. Patients should be monitored for the emergence of serotonin syndrome. The concomitant use of CYMBALTA with MAOIs intended to treat psychiatric disorders is contraindicated. CYMBALTA should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking CYMBALTA. CYMBALTA should be discontinued before initiating treatment with the MAOI . John’s Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. Treatment with CYMBALTA and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. Abnormal Bleeding. SSRIs and SNRIs, including CYMBALTA, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti- inflammatory drugs, warfarin, and other anti- coagulants may add to this risk. Case reports and epidemiological studies (case- control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2017
Categories |